Volpara Solutions Celebrates 10 Years of Striving to Save Families from Breast Cancer

WELLINGTON, New Zealand, April 4, 2019 /PRNewswire/ -- Celebrating its 10th Anniversary in 2019, Volpara Solutions remains committed to helping breast imaging centers achieve improved mammographic sensitivity and detect breast cancers earlier. Since launching Volpara^®Density^™ software in 2010, the company has pioneered a robust suite of quantitative breast imaging tools that enable personalized measurements of volumetric density, breast compression, and breast positioning on every mammogram—factors designed to maintain image quality and provide critical insight for breast imaging workflow.

Volpara boasts many accomplishments in its 10-year history. Some of the most notable include the following:

• Over 100 peer-reviewed papers, making VolparaDensity the most clinically validated automatic, volumetric breast density assessment software in the world
• Density assessments for more than 20 million women across 37 countries
• Software installed in more than 300 leading facilities worldwide, including the top two cancer centers in the United States, according to the latest hospital rankings from US News & World Report
• More than 1 million mammographic and tomosynthesis studies evaluated for positioning and compression stored in the Volpara^®Enterprise^™ cloud
• Recurring revenue growth of over 3,000% since listing on the ASX in 2016

"Volpara was founded for very personal reasons, as we each had friends and family members die of breast cancer. However, with more than 500,000 breast cancers deaths worldwide each year, our vision quickly expanded to a focus on helping save all families from breast cancer," said Ralph Highnam, PhD, founder and CEO, Volpara Solutions. "Building on the hugely successful adoption of VolparaDensity over the past 10 years, we have been able to make women and physicians understand the importance of breast density and help shift the conversation to risk and personalized medicine. We are extremely proud of the progress we've made and thank all of our employees, industry partners, researchers, and customers as we look forward to the next 10 years of progress."

According to Highnam, the achievements of the first 10 years may best be summarized by a recent customer comment: "with Volpara, we are making screening more accurate, more comfortable, safer, more cost-effective and making a difference daily."

Volpara Solutions will showcase its complete suite of quantitative breast imaging tools at SBI (Booth #203), including an updated version of VolparaDensity software, which now more accurately reflects breast density from images captured using the Hologic^® SmartCurve™ system. Volpara will also showcase a new version of Volpara^®Live!™, mammography's first real-time decision support system available at the point of care. VolparaLive! automatically analyzes patient positioning and compression and provides real-time feedback to technologists. Designed to help technologists acquire consistent, high-quality mammograms, VolparaLive! puts data in the technologists' hands before the patient leaves the room. This helps optimize productivity, reduce costs through the reduction of retakes, and increase staff effectiveness.

VolparaEnterprise is the only solution available that provides a comprehensive assessment of image quality on every mammogram and tomosynthesis exam, including positioning and compression, which the FDA attributes as the cause of most clinical image deficiencies. As one of the clinical applications within VolparaEnterprise, VolparaDensity provides radiologists with automated, objective volumetric breast density assessments and a breast density category shown to correlate to BI-RADS 4th and 5th Editions. It is CE-marked and cleared by the FDA, Health Canada, and the TGA.

About Volpara Solutions
Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand. Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaEnterprise is a suite of quantitative breast imaging tools for personalized measurements of density, patient-specific x‑ray dose, breast compression, breast positioning, and other factors designed to provide critical insight for breast imaging workflow. VolparaLive! provides technologists with a real-time decision support at the point of care to assess image quality. For more information, visit www.volparasolutions.com.

SOURCE Volpara Solutions

Related Links

http://www.volparadensity.com